Janus kinases (JAK) modulate type 2 cytokines involved in the pathogenesis of AD, and ruxolitinib selectively inhibits JAK1 and JAK2 [1]. The results of the phase 3 trials TRuE-AD1 (NCT03745638) and TRuE-AD2 (NCT03745651) demonstrated sustained action of ruxolitinib cream on inflammation and itch in AD compared with a vehicle, with a good safety profile. The studies tested ruxolitinib 0.75% and 1.5% cream versus vehicle with the primary endpoint of treatment success in the IGA defined as a score 0/1 with at least 2 grades of improvement from baseline.
āPublished literature describing patients with AD aged 65 years and older is limited,ā said Prof. Jacek Szepietowksi (Wroclaw Medical University, Poland) [2]. Thus, Prof. Szepietowksi and colleagues assessed the efficacy and safety of the topical JAK1/JAK2 inhibitor ruxolitinib in this population at week 8 with pooled data of the ā„65-year-old patients from TRuE-AD1 and TruE-AD2 [2].
Among the 1,249 original participants (aged 12ā85 years), 115 (9.2%) were included in the presented analysis. The median age of this older cohort was 70 years and 55.7% were women. The clinical characteristics showed a mean baseline Eczema Area and Severity Index (EASI) score of 7.7 and IGA of 3 (i.e. moderate) in 73% of participants. Prof. Szepietowksi added that ā70% of patients had an itch numeric rating scale (NRS) score of at least 4 and the median duration of AD was 20 years, indicating long-standing disease.ā
The primary endpoint of IGA 0/1 was achieved by 60.5% in the 1.5% ruxolitinib cream arm, which was significantly more than the 15.4% receiving vehicle (P<0.001). The 0.75% regimen led to IGA 0/1 in 32% of patients. Also, the 8-week results for EASI 50, 75, and 90 reflected time-dependent and dose-dependent ameliorations. EASI 50 was reached by 64% (0.75% dosage) and 84.2% (1.5% dosage) versus 38.5% on placebo. The corresponding outcomes for EASI 75 were 44.0% and 73.7% versus 15.4%, respectively. EASI 90 was seen in 26% and 50% of the respective active treatment arms versus 3.8% on the vehicle.
Among the key secondary endpoints were differences in itch NRS score and Patient-Reported Outcomes Measurement Information System (PROMIS) sleep disturbance. Depending on the cream concentration, a proportion of 53.8% (1.5% cream) and 36.1% (0.75% cream) had a ā„4-point score reduction in itch NRS compared with 17.6% in the placebo group. As for a decrease in sleep disturbance, about a third in the higher-dosed arm experienced a ā„6-point decrease in their PROMIS score.
Prof. Szepietowksi pointed out that in terms of safety, ruxolitinib cream only led to a low rate of application site reactions and no safety findings of systemic JAK inhibition. He furthermore stressed that no serious treatment-emergent adverse events were observed. āThese results demonstrate the potential of ruxolitinib cream as an effective and well-tolerated topical treatment for patients with AD aged 65 years and older,ā Prof. Szepietowksi concluded.
- Papp K, et al. J Am Acad Dermatol. 2021 Oct;85(4):863-872.
- Szepietowski JC. Efficacy and safety of ruxolitinib cream among patients aged ā„65 years with atopic dermatitis: pooled results from two phase 3 studies. FC01.01, EADV Congress 2021, 29 Septā2 Oct.
Copyright Ā©2021 Medicom Medical Publishers
Posted on
Previous Article
« Novel and upcoming targeted AD treatment Next Article
Efficacious 2-year AD control with IL-13 inhibitor tralokinumab »
« Novel and upcoming targeted AD treatment Next Article
Efficacious 2-year AD control with IL-13 inhibitor tralokinumab »
Table of Contents: EADV 2021
Featured articles
Letter from the Editor
Long-term disease control in AD could be in reach with anti-OX40 antibody KHK4083
Late-Breaking News
Targeting OX40 in the treatment of atopic dermatitis meets expectations
Superior EASI scores after switch from dupilumab to upadacitinib
CSU: Novel agent targeting Brutonās tyrosine kinase leads to disease control
Novel JAK3/TEC blocker leads to maintained re-pigmentation in vitiligo
TYK2 inhibitor deucravacitinib shows impressive long-term response in psoriasis
Tapinarof cream for psoriasis leads to high clearance rates and remittive effect
CSU: Ligelizumab likely safe and effective for adolescents
Long-term disease control in AD could be in reach with anti-OX40 antibody KHK4083
Topical JAK1/JAK2 inhibitor effective in vitiligo
Abrocitinib demonstrates fast itch control and skin clearance in atopic dermatitis
AD patients with stable response fare well with a monthly dose of tralokinumab
Opioid receptor agonist difelikefalin disappoints in AD
Atopic Dermatitis: State of the Art
Upadacitinib beats dupilumab in different body regions
Efficacious 2-year AD control with IL-13 inhibitor tralokinumab
Ruxolitinib cream: a safe treatment for elderly AD patients
Novel and upcoming targeted AD treatment
Psoriasis: What's New?
Existing and upcoming small molecules in psoriasis
Treating psoriasis during pregnancies
A patient-related approach to freedom of disease
Ixekizumab superior to secukinumab in real-world psoriasis study
Nail psoriasis: An important target to be treated
Grand debate: Is psoriasis a systemic or skin-only disease?
Spotlight on Alopecia Areata
JAK1/2: A promising novel treatment target in alopecia areata
Alopecia areata: encouraging response rates with JAK3/TEC inhibition
Related Articles
November 18, 2021
Existing and upcoming small molecules in psoriasis
November 18, 2021
Targeting OX40 in the treatment of atopic dermatitis meets expectations
November 18, 2021
Letter from the Editor
Ā© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy